The third quarter will answer crucial questions about the near-term future of digital health.
Will the upstart companies that enabled care and clinical trials to continue remotely during the pandemic have the same resonance and revenue growth as it recedes? Will they keep finding exit avenues via acquisitions, IPOs, or SPAC mergers? The next three months will provide a readout on whether the fundamentals of the industry are really as strong as year-to-date fundraising and exit activity would suggest.
Create a display name to comment
This name will appear with your comment